Windlas Biotech Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results in a meeting held on February 5, 2026. The meeting commenced at 4:00 PM and concluded at 5:20 PM. For the quarter ended December 31, 2025, the company reported a consolidated profit after tax of ₹150.02 crore (1,500.2 million INR) and a standalone profit after tax of ₹149.54 crore (1,495.4 million INR). For the nine months ended December 31, 2025, the consolidated profit after tax was ₹504.66 crore (5,046.6 million INR), and the standalone profit after tax was ₹504.19 crore (5,041.9 million INR). The company also informed about the closure and dissolution of its non-operative wholly-owned subsidiary, Windlas Inc. USA. The application for dissolution will be initiated as per the laws of Delaware, USA. Additionally, the company has been actively managing its employee stock option plans (ESOPs). During the current financial year, 117,928 equity shares were allotted under ESOP schemes. The company also introduced the ‘Windlas Plan 2025’ to grant up to 590,250 options/units to eligible employees, with approvals obtained from the board, shareholders, and stock exchanges. As of September 15, 2025, 570,500 options/units were granted.